Company Advanced Life Sciences Holdings, Inc.

Advanced Life Sciences Holdings, Inc. is a United States-based biopharmaceutical company. The Company is engaged in the discovery, development, and commercialization of drugs in the therapeutic areas of infection, cancer, and respiratory diseases. The Company’s Restanza is an antibiotic in development for the treatment of life-threatening infections including community-acquired bacterial pneumonia and biodefense pathogens including anthrax, plague, and tularemia. Its ALS-886 is a therapeutic molecule in preclinical studies is being developed for the treatment intended to reduce and prevent the tissue damage associated with diseases such as Adult Respiratory Distress Syndrome (ARDS). Its ALS-357 is a natural product in preclinical studies has demonstrated specific anti-tumor activity against malignant melanoma. Preclinical studies have shown that direct injection of ALS-357 into grafted human tumors induced apoptosis, programmed cell death, within the tumors.